Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis

Cancer Research

Volumn 63, Issue 16, 2003, Pages 4862-4871

  Riley, Rebeccah R ^a   Duensing, Stefan ^b   Brake, Tiffany ^c   Münger, Karl ^b   Lambert, Paul F ^c   Arbeit, Jeffrey M ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS PROTEIN E6; VIRUS PROTEIN E7;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTROSOME; CONTROLLED STUDY; FEMALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; UTERINE CERVIX CARCINOMA; WART VIRUS;

ANIMALS; APOPTOSIS; CENTROSOME; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; MICE; MICE, TRANSGENIC; NEOPLASM STAGING; ONCOGENE PROTEINS, VIRAL; OPEN READING FRAMES; PAPILLOMAVIRIDAE; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 0042440926     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Münger, K. The role of human papillomaviruses in human cancers. Front. Biosci., 7: d641-649, 2002.
2. zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer, 2: 342-350, 2002.
3. zur Hausen, H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr. Top. Microbiol. Immunol., 186: 131-156, 1994.
4. Münger, K. The molecular biology of cervical cancer. J. Cell. Biochem. Suppl., 23: 55-60, 1995.
5. Münger, K., Basile, J. R., Duensing, S., Eichten, A., Gonzalez, S. L., Grace, M., and Zacny, V. L. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene, 20; 7888-7898, 2001.
6. McMurray, H., Nguyen, D., Westbrook, T., and McCance, D. Biology of human papillomaviruses. Int. J. Exp. Pathol., 82: 15-33, 2001.
7. Mantovani, F., and Banks, L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene, 20: 7874-7887, 2001.
8. Jones, D. L., and Münger, K. Interactions of the human papillomavirus E7 protein with cell cycle regulators. Semin. Cancer Biol., 7: 327-337, 1996.
9. Jones, D. L., Thompson, D. A., and Münger, K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology, 239: 97-107, 1997.
10. Scheffner, M., Wemess, B., Huibregste, J., and Howley, P. The E6 oncoprotein encoded by human papillomavirus type 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
11. Antinore, M. J., Birrer, M. J., Patel, D., Nader, L., and McCance, D. J. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J., 15: 1950-1960, 1996.
12. Barbosa, M. S., and Schlegel, R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene, 4: 1529-1532, 1989.
13. Howley, P. M., Münger, K., Werness, B. A., Phelps, W. C., and Schlegel, R. Molecular mechanisms of transformation by the human papillomaviruses. Princess Takamatsu Symp., 20: 199-206, 1989.
14. Villa, L. L., and Schlegel, R. Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region. Virology, 181: 374-377, 1991.
15. Münger, K., Phelps, W. C., Bubb, V., Howley, P. M., and Schlegel, R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol., 63: 4417-4421, 1989.
16. Arbeit, J. M., Münger, K., Howley, P. M., and Hanahan, D. Neuroepithelial carcinomas in mice transgenic with human papillomavirus type 16 E6/E7 ORFs. Am. J. Pathol., 142: 1187-1197, 1993.
17. Griep, A. E., Herber, R., Jeon, S., Lohse, J. K., Dubielzig, R. R., and Lambert, P. F. Tumorigenicity by human papillomavirus type 16 E6 and E7 in transgenic mice correlates with alterations in epithelial cell growth and differentiation. J. Virol., 67, 1373-1384, 1993.
18. Lambert, P., Pan, H., Pilot, H., and et al. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc. Natl. Acad. Sci. USA, 90: 5583-5587, 1993.
19. Arbeit, J. M., Münger, K., Howley, P. M., and Hanahan, D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol., 68: 4358-4368. 1994.
20. Searle, P., Thomas, D., Faulkner, K., and Tinsley, J. Stomach cancer in transgenic mice expressing human papillomavirus type 16 genes from a keratin promoter. J. Gen. Virol., 75: 1125-1137, 1994.
21. Kondoh, G., Murata, Y., Aozasa, K., Yutsudo, M., and Hakura, A. Very high incidence of germ cell tumorigenesis (seminomagenesis) in human papillomavirus type 16 transgenic mice. J. Virol. 65: 3335-3339, 1991.
22. Adams, M., Borysiewicz, L., Fiander, A., Man, S., Jasani, B., Navabi, H., Lipetz, C., Evans, A. S., and Mason, M. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine, 19: 2549-2556, 2001.
23. Di Lonardo, A. D., Marcante, M. L., Poggiali, F., Hamsoikova, E. and Venuti, A. Egg yolk antibodies against the E7 oncogenic protein of human papillomavirus type 16. Arch. Virol., 146: 117-125, 2001.
24. Pumpens, P., Razanskas, R., Pushko, P., Renhof, R., Gusars, I., Skrastina, D., Ose, V., Borisova, G., Sominskaya. I., Petrovskis, I., Jansons, J., and Sasnauskas, K. Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes. Intervirology, 45: 24-32, 2002.
25. Galloway, D. A. Papillomavirus oncoproteins as vaccine candidates. Lancet, 347: 1498-1499, 1996.
26. Schiller, J. T., and Hidesheim, A. Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J. Clin. Virol., 19: 67-74, 2000.
27. Phelps, W. C., Bames, J. A., and Lobe, D. C. Molecular targets for human papillomaviruses: prospects for antiviral therapy. Antivir. Chem. Chemother., 9: 359-377, 1998.
28. Underwood, M. R., Shewchuk, L. M., Hassell, A. M., and Phelps, W. C. Searching for antiviral drugs for human papillomaviruses. Antivir. Ther., 5: 229-242, 2000.
29. Beerheide, W., Sim, M. M., Tan, Y. J., Bernard, H. U., and Ting, A. E. Inactivation of the human papillomavirus-16 E6 oncoprotein by organic disulfides. Bioorg. Med. Chem., 8: 2549-2560. 2000.
30. Arbeit, J. M., Howley, P. M., and Hanahan, D. Chronic estrogen induced cervical and vaginal squamous carcinogenesis in HPV16 transgenic mice. Proc. Natl. Acad. Sci. USA, 93: 2930-2935, 1996.
31. Elson, D. A., Riley, R. R., Lacey, A., Thordarson, G., Talamantes, F., and Arbeit, J. M. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res., 60: 1267-1275, 2000.
32. Herber, R., Liem, A., Pitot, H., and Lambert, P. F. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J. Virol., 70: 1873-1881, 1996.
33. Song, S., Pitot, H. C., and Lambert, P. F. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J. Virol., 73: 5887-5893, 1999.
34. Litvak, K., Flood, S., Marmato, J., Giusti, W., and Deetz, K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Method. Appl., 4: 357-362, 1995.
35. Elson, D. A., Thurston, G., Huang, L. E., Ginzinger, D. G., McDonald, D. M., Johnson, R. S., and Arbeit, J. M. Induction of hypervascularity without leak or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α Genes Dev., 15: 2520-2532, 2001.
36. Arbeit, J. M., Riley, R. R., Huey, B., Porter, C., Kelloff, G., Lubet, R., Ward, J. M., and Pinkel, D. DFMO chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice. Cancer Res., 59: 3610-3620, 1999.
37. Duensing, S., Lee, L. Y., Duensing, A., Basile, J., Piboonniyom, S., Gonzalez, S., Crum, C. P., and Münger, K. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc. Natl. Acad. Sci. USA, 97: 10002-10007, 2000.
38. Pan, H., and Griep, A. Altered cell cycle regulation in the lens of HPV16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev., 8: 1285-1299, 1994.
39. Song, S., Liem, A., Miller, J. A., and Lambert, P. F. Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology, 267: 141-150, 2000.
40. Song, S., Gulliver, G. A., and Lambert, P. F. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc. Natl. Acad. Sci. USA, 95, 2290-2295, 1998.
41. Crum, C., and Nuovo, G. Genital Papillomaviruses and Related Neoplasms, pp. 16-19. New York: Raven Press, 1991.
42. Broders, A. Practical points on the microscopic grading of carcinoma. New York State J. Med., 32: 667-671, 1932.
43. Gulliver, G. A., Herber, R. L., Liem, A., and Lambert, P. F. Both conserved region 1 (CR1) and CR2 of the human papillomavirus type 16 E7 oncogene are required for induction of epidermal hyperplasia and tumor formation in transgenic mice. J. Virol., 71: 5905-5914, 1997.
44. Jones, D. L., Alani, R. M., and Münger, K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev., 11: 2101-2111, 1997.
45. Scheffner, M., Münger, K., Byme, J. C., and Howley, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 88: 5523-5527, 1991.
46. Demers, G. W., Halbert, C. L., and Galloway, D. A. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology, 198: 169-174, 1994.
47. Levine, A. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
48. Talis, A. L., Huibregtse, J. M., and Howley, P. M. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J. Biol. Chem. 273: 6439-6445, 1998.
49. Scheffner, M., Huibregtse, J. M., Vierstra, R. D., and Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 75: 495-505, 1993.
50. Howes, K. A., Ransom, N., Papermaster, D. S., Lasudry, J. G., Albert, D. M., and Windle, J. J. Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev., 8: 1300-1310, 1994.
51. Tarapore, P., and Fukasawa, K. Loss of p53 and centrosome hyperamplification. Oncogene, 21: 6234-6240, 2002.
52. Duensing, S., and Münger, K. Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability. Oncogene, 21: 6241-6248, 2002.
53. Hanahan, D., and Weinberg, R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000.
54. Korach, K. Insights from the study of animals lacking functional estrogen receptor. Science (Wash. DC), 266: 1524-1527, 1994.
55. Webb, P., Lopez, G., Uht, R., and Kushner, P. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol., 9: 443-456, 1995.
56. Duensing, S., Duensing, A., Flores, E. R., Do, A., Lambert, P. F., and Münger, K. Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. J. Virol., 75: 7712-7716, 2001.
57. Duensing, S., Duensing, A., Crum, C. P., and Münger, K. Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res., 61: 2356-2360, 2001.
58. Auborn, K., Woodworth, C., DiPaolo, J., and Bradlow, H. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int. J. Cancer, 49: 867-869, 1990.
59. Mesia-Vela, S., Sanchez, R. I., Li, J. J., Li, S. A., Conney, A. H., and Kauffman, F. C. Catechol estrogen formation in liver microsomes from female ACI and Sprague-Dawley rats: comparison of 2- and 4-hydroxylation revisited. Carcinogenesis (Lond.), 23: 1369-1372, 2002.
60. Zhu, B. T., and Conney, A. H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis (Lond.), 19: 1-27, 1998.
61. Hana, V., and Murphy, L. J. Interdependence of epidermal growth factor and insulin-like growth factor-I expression in the mouse uterus. Endocrinology, 135: 107-112, 1994.
62. Sato, T., Wang, G., Hardy, M. P., Kurita, T., Cunha, G. R., and Cooke, P. S. Role of systemic and local IGF-I in the effects of estrogen on growth and epithelial proliferation of mouse uterus. Endocrinology, 143: 2673-2679, 2002.
63. Gray, K., Eitzman, B., Raszmann, K., Steed, T., Geboff, A., McLachlan, J., and Bidwell, M. Coordinate regulation by diethylstilbestrol of the platelet-derived growth factor-A (PDGF-A) and -B chains and the PDGF receptor α- and β-subunits in the mouse uterus and vagina: potential mediators of estrogen action. Endocrinology, 136: 2325-2340, 1995.
64. Paria, B. C., Das, S. K., Huet-Hudson, Y. M., and Dey, S. K. Distribution of transforming growth factor a precursors in the mouse uterus during the periimplantation period and after steroid hormone treatments. Biol. Reprod., 50: 481-491, 1994.
65. Kuhara, A., Tsuji, M., Tsujimura, T., Sugihara, A., Yamada, N., and Terada, N. Comparison of sensitivities of uterine cells in their proliferation responding to epidermal growth factor and estrogen between neonatal and postneonatal mice. In Vivo, 13: 487-491, 1999.
66. Slowey, M. J., Verhage, H. G., and Fazleabas, A. T. Epidermal growth factor, transforming growth factor-α, and epidermal growth factor receptor localization in the baboon (Papio anubis) uterus during the menstrual cycle and early pregnancy. J. Soc. Gynecol. Investig., 1: 277-284, 1994.
67. Sherman, L., Itzhaki, H., Jackman, A., Chen, J. J., Koval, D., and Schlegel, R. Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16 E6: study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP. Virology, 292: 309-320, 2002.
68. Liu, Y., Chen, J. J., Gao, Q., Dalal, S., Hong, Y., Mansur, C. P., Band, V., and Androphy, E. J. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J. Virol., 73: 7297-7307, 1999.
69. Kiyono, T., Hiraiwa, A., Fujita, M., Hayashi, Y., Akiyama, T., and Ishibashi, M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. USA, 94: 11612-11616, 1997.
70. Tong, X., and Howley, P. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proceedings National Academy of Sciences, USA, 94: 4412-4417, 1997.
71. Klingelhutz, A. J., Foster, S. A., and McDougall, J. K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature (Lond.), 380: 79-82, 1996.
72. Veldman, T., Horikawa, I., Barrett, J. C., and Schlegel, R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J. Virol., 75: 4467-4472, 2001.
73. Stoler, A., Stenback, F., and Balmain, A. The conversion of mouse skin squamous cell carcinomas to spindle cell carcinomas is a recessive event. J. Cell Biol., 122: 1103-1117, 1993.